Application of physiologically based absorption modeling to formulation development of a low solubility, low permeability weak base: Mechanistic investigation of food effect

AAPS PharmSciTech

Volumn 15, Issue 2, 2014, Pages 400-406

  Zhang, Hefei ^a   Xia, Binfeng ^a   Sheng, Jennifer ^a   Heimbach, Tycho ^a   Lin, Tsu Han ^a   He, Handan ^a   Wang, Yanfeng ^a   Novick, Steven ^a   Comfort, Ann ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

GastroPlus; particle size; physiologically based pharmacokinetics; precipitation; solubility

Indexed keywords

BASE; ALKALI;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG PENETRATION; DRUG SOLUBILITY; FEASIBILITY STUDY; FEMALE; FOOD; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SIMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; CHEMICAL MODEL; CHEMISTRY; PERMEABILITY; SOLUBILITY;

ALKALIES; FOOD-DRUG INTERACTIONS; MODELS, CHEMICAL; PERMEABILITY; SOLUBILITY;

EID: 84898036483     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-014-0075-1     Document Type: Article

References (21)

1. Yu LX, Lipka E, Crison JR, Amidon GL. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv Drug Deliv Rev. 1996;19(3):359-76.
2. Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev. 2001;50 Suppl 1:S41-67.
3. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413-20.
4. Fleisher D, Li C, Zhou Y, Pao L-H, Karim A. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet. 1999;36(3):233-54.
5. Parrott N, Lukacova V, Fraczkiewicz G, Bolger MB. Predicting pharmacokinetics of drugs using physiologically based modeling - application to food effects. AAPS J. 2009;11(1):45-53.
6. Gu C-H, Li H, Levons J, Lentz K, Gandhi RB, Raghavan K, et al. Predicting effect of food on extent of drug absorption based on physicochemical properties (Pharmaceutical Research (2007) DOI: 10.1007/s11095-007-9236-1). Pharm Res. 2008;25(4):979.
7. Heimbach T, Xia BF, Lin TH, He HD. Case studies for practical food effect assessments across BCS/BDDCS class compounds using in silico, in vitro, and preclinical in vivo data. AAPS J. 2013;15(1):143-58.
8. Wagner C, Jantratid E, Kesisoglou F, Vertzoni M, Reppas C, Dressman JB. Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model. Eur J Pharm Biopharm. 2012;82(1):127-38.
9. Xia BF, Heimbach T, Lin TH, Li SF, Zhang HF, Sheng J, et al. Utility of physiologically based modeling and preclinical in vitro/in vivo data to mitigate positive food effect in a BCS class 2 compound. AAPS Pharmscitech. 2013;14(3):1255-66.
10. Usansky HH, Sinko PJ. Estimating human drug oral absorption kinetics from Caco-2 permeability using an absorption-disposition model: model development and evaluation and derivation of analytical solutions for k(a) and F(a). J Pharmacol Exp Ther. 2005;314(1):391-9.
11. Lu AT, Frisella ME, Johnson KC. Dissolution modeling: factors affecting the dissolution rates of polydisperse powders. Pharm Res. 1993;10(9):1308-14.
12. Gardner JD, Ciociola AA, Robinson M. Measurement of meal-stimulated gastric acid secretion by in vivo gastric autotitration. J Appl Physiol. 2002;92(2):427-34.
13. Dressman JB, Berardi RR, Dermentzoglou LC, Russell TL, Schmaltz SP, Barnett JL, et al. Upper gastrointestinal (GI) Ph in young, healthy men and women. Pharm Res. 1990;7(7):756-61.
14. Muller RH, Peters K. Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique. Int J Pharm. 1998;160(2):229-37.
15. Benet LZ, Broccatelli F, Oprea TI. BDDCS applied to over 900 drugs. AAPS J. 2011;13(4):519-47.
16. Shono Y, Jantratid E, Dressman JB. Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir. Eur J Pharm Biopharm. 2011;79(2):349-56.
17. Mithani SD, Bakatselou V, TenHoor CN, Dressman JB. Estimation of the increase in solubility of drugs as a function of bile salt concentration. Pharm Res. 1996;13(1):163-7.
18. Nicolaides E, Galia E, Efthymiopoulos C, Dressman JB, Reppas C. Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data. Pharm Res. 1999;16(12):1876-82.
19. Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, et al. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release. 2006;111(1-2):56-64.
20. Wu Y, Loper A, Landis E, Hettrick L, Novak L, Lynn K, et al. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm. 2004;285(1-2):135-46.
21. Kesisoglou F, Wu YH. Understanding the effect of API properties on bioavailability through absorption modeling. AAPS J. 2008;10(4):516-25.